Search

Rosario Costas-Muñiz’s work is helping Latino patients at MSK and across Latin America.

… Friday, May 27, 2022 As a young girl growing up on the south side of Puerto Rico, Rosario Costas-Muñiz, PhD , felt a calling to help people with the mental health side effects of a cancer diagnosis. Today, she is a psycho-oncologist at Memorial Sloan Kettering Cancer Center. She focuses on the mental

El trabajo de Rosario Costas-Muñiz ayuda a pacientes latinos en MSK y en toda América Latina.

… Friday, May 27, 2022 Cuando era una niña y crecía en el lado sur de Puerto Rico, la doctora Rosario Costas-Muñiz , sintió el llamado de ayudar a las personas a lidiar con los efectos secundarios de un diagnóstico de cáncer en la salud mental. En la actualidad, es psicooncóloga en el Memorial Sloan Kettering

Craig B. Thompson, MD, has been named the new President and Chief Executive Officer of Memorial Sloan Kettering Cancer Center effective November 2, 2010. His appointment concludes a search that began in January 2010.

… Tuesday, August 10, 2010 Craig B. Thompson, MD , has been named the new President and Chief Executive Officer of Memorial Sloan Kettering Cancer Center effective November 2, 2010. His appointment concludes a search that began in January 2010. He succeeds Harold Varmus, MD, who left Memorial Sloan Kettering

Research recently published by MSK scientists suggests that the best way to fight dangerous bacteria may be with other bacteria.

… Tuesday, June 20, 2017 Summary People with cancer are particularly susceptible to infections because treatment often damages their immune system. Now research is suggesting that the best way to combat these dangerous infections may be with other, nonharmful bacteria. Highlights Antibiotics are an important

A new study by a team of 12 thoracic surgeons at Memorial Sloan Kettering Cancer Center (MSK), published recently in the Annals of Surgery,([i]) is the first to identify a comprehensive list of clinical factors significantly associated with referring patients with stage 1 NSCLC to SBRT.

… Tuesday, November 5, 2024 Minimally invasive surgery (MIS) and stereotactic body radiotherapy (SBRT) are both used to treat stage 1 non-small cell lung cancer (NSCLC). While MIS remains the standard of care for patients with operable disease, selecting which patients should be referred for SBRT has been

A newly identified group of immunosuppressive cells could provide insight into the effects of immunotherapy drugs.

… Tuesday, June 12, 2018 Summary MSK researchers have identified a new group of immunosuppressive cells that are affected in opposite ways by two common checkpoint inhibitors often given in combination. These cells are easily detectable in the blood and could help doctors make immunotherapy work better

MSK physicians and researchers discussed the latest trends in breast cancer research at the annual meeting held in San Antonio.

… Thursday, December 9, 2021 This week at the annual San Antonio Breast Cancer Symposium (SABCS), MSK researchers discussed some of the latest advances in breast cancer treatment and led educational sessions about improving ways to treat and manage the disease. Here are some of the noteworthy presentations

On Tuesday, December 2, MSK hosted "Demo Day 2025," a strong follow-up to the institution’s November 2025 “Innovation with Lasting Impact Summit” on entrepreneurship and innovation.

… Monday, January 12, 2026 On Tuesday, December 2, MSK hosted “ Demo Day 2025 ,” a strong follow-up to the institution’s November 2025 “ Innovation with Lasting Impact Summit ” on entrepreneurship and innovation. Fifteen cutting-edge companies selected to work with MSK’s laboratory, clinical, and digital

Microsatellite instability (MSI) and DNA mismatch repair (MMR) deficiencies can predict Lynch syndrome (LS) across tumor types, according to researchers from Memorial Sloan Kettering Cancer Center (MSK), who presented this retrospective data analysis in a press conference at the annual meeting of the American Society of Clinical Oncology. This finding suggests that LS is linked to more types of cancer than previously thought, prompting a call for germline testing for LS in all individuals with MSI-high (MSI-H)/mismatch repair deficient (MMR-D) tumors.

… Saturday, June 2, 2018 Microsatellite instability (MSI) and DNA mismatch repair (MMR) deficiencies can predict Lynch syndrome (LS) across tumor types, according to researchers from Memorial Sloan Kettering Cancer Center (MSK), who presented this retrospective data analysis in a press conference at the

… Wednesday, August 15, 2018 Summary A woman with an aggressive pituitary tumor responded well to immunotherapy. This successful treatment may lead to a clinical trial testing this approach in more people. Tumors of the pea-size pituitary gland, which sits at the base of the brain and secretes hormones